ArticleJournal of virology2017
Protective Efficacies of Formaldehyde-Inactivated Whole-Virus Vaccine and Antivirals in a Murine Model of Coxsackievirus A10 Infection.
Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Pathological characteristics of coxsackievirus A14 in neonatal mice model.Virology journal · 2026Article
- Arginine depletion-induced autophagy and metabolic dysregulation are involved in the disease severity of hand, foot, and mouth disease.Virulence · 2025Article
- A lethal juvenile mouse model for the evaluation of antiviral reagents against coxsackievirus A4.iScience · 2025Article
- Pathological characteristics of a murine oral coxsackievirus A10 infection model.Journal of virology · 2025Article
- Molecular docking, derivatization, characterization and biological assays of amantadine.Future medicinal chemistry · 2024Article
- Humoral and cellular immunogenicity and efficacy of a coxsackievirus A10 vaccine in mice.Emerging microbes & infections · 2023Article
- Non-Polio Enterovirus Surveillance in the Ural Federal District and Western Siberia, 2022: Is There a Need for a Vaccine?Vaccines · 2023Article
- VP2 residue N142 of coxsackievirus A10 is critical for the interaction with KREMEN1 receptor and neutralizing antibodies and the pathogenicity in mice.PLoS pathogens · 2023Article
- Human SCARB2 Acts as a Cellular Associator for Helping Coxsackieviruses A10 Infection.Viruses · 2023Article
- Current status of hand-foot-and-mouth disease.Journal of biomedical science · 2023Review
- TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases.PLoS neglected tropical diseases · 2023Article
- Identification of a neutralizing linear epitope within the VP1 protein of coxsackievirus A10.Virology journal · 2022Article
- Pathogenic analysis of coxsackievirus A10 in rhesus macaques.Virologica Sinica · 2022Article
- Article
- Efficacy of a coxsackievirus A6 vaccine candidate in an actively immunized mouse model.Emerging microbes & infections · 2021Article
- The Disruption of the Endothelial Barrier Contributes to Acute Lung Injury Induced byInternational journal of molecular sciences · 2021Article
- From Monovalent to Multivalent Vaccines, the Exploration for Potential Preventive Strategies Against Hand, Foot, and Mouth Disease (HFMD).Virologica Sinica · 2021Review
- Efficacy of Coxsackievirus A5 Vaccine Candidates in an Actively Immunized Mouse Model.Journal of virology · 2021Article
- Neonatal Murine Model of Coxsackievirus A2 Infection for the Evaluation of Antiviral Therapeutics and Vaccination.Frontiers in microbiology · 2021Article
- Enterovirus-Associated Hand-Foot and Mouth Disease and Neurological Complications in Japan and the Rest of the World.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coxsackievirus A10 (CVA10) is one of the major pathogens associated with hand, foot, and mouth disease (HFMD). CVA10 infection can cause herpangina and viral pneumonia, which can be complicated by severe neurological sequelae. The morbidity and mortality of CVA10-associated HFMD have been increasing in recent years, particularly in the pan-Pacific region. There are limited studies, however, on the pathogenesis and immunology of CVA10-associated HFMD infections, and few antiviral drugs or vaccines have been reported. In the present study, a cell-adapted CVA10 strain was employed to inoculate intramuscularly 5-day-old ICR mice, which developed significant clinical signs, including reduced mobility, lower weight gain, and quadriplegia, with significant pathology in the brain, hind limb skeletal muscles, and lungs of infected mice in the moribund state. The severity of illness was associated with abnormally high expression of the proinflammatory cytokine interleukin 6 (IL-6). Antiviral assays demonstrated that ribavirin and gamma interferon administration could significantly inhibit CVA10 replication both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.